As GLP-1s began reshaping obesity treatment, the company launched a dedicated GLP-1 care track, designed to sit alongside pharmacotherapy rather than replace it
International Shipping International customers are responsible for understanding and complying with their local laws and import regulations
Prescription delivered to your door
The New England Journal of Medicine commentary accompanying SURPASS-2 stated: "The dual incretin approach appears to exploit receptor crosstalk in ways that amplify downstream insulin secretion beyond what GLP-1 receptor agonism alone can achieve at comparable tolerability." [30] SURPASS-1: Monotherapy Benchmark SURPASS-1 (N=478) established monotherapy efficacy, with tirzepatide 15 mg reducing A1C by 2.07 percentage points and body weight by 9.5 kg at 40 weeks versus placebo [31]
During this discussion, they may evaluate your individual health conditions, such as your risk for diabetic retinopathy, hypoglycemia, or pancreatitis, especially if you are currently using sulfonylureas or other blood-sugarlowering medications
